RecruitingPhase 4NCT04372277
Taltz in Combination With Enstilar for Psoriasis
Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients
Sponsor
Psoriasis Treatment Center of Central New Jersey
Enrollment
25 participants
Start Date
Apr 28, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
Enstilar in combination with Taltz for plaque psoriasis.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Enstilar for people with psoriasis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEnstilar
topical Enstilar foam
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04372277
Related Trials
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT0381634552 locations
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
NCT065741781 location
PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
NCT076486022 locations
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT065994111 location
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
NCT075827836 locations